Context Therapeutics, a Phase 2 biotech developing therapeutics for female cancers, filed on Thursday with the SEC to raise up to $15 million in an initial public offering.
Context Therapeutics is advancing its sole clinical candidate, ONA-XR, for the treatment of ovarian, breast, and endometrial cancer in multiple clinical trials, both as a monotherapy and in combination with other therapeutics. In 2019, the company began a Phase 2 trial of ONA-XR in ovarian cancer patients who express high levels of progesterone receptor (PR+), with preliminary results expected in the second half of 2021. In 2020, the company also initiated a Phase 2 trial of ONA-XR in combination with Arimidex in PR+ endometrial cancer patients, with preliminary data expected in the first half of 2022. Memorial Sloan Kettering Cancer Center and Wisconsin Oncology Network are also conducting trials of ONA-XR in breast cancer in collaboration with the company.
The Philadelphia, PA-based company was founded in 2015 and plans to list on the Nasdaq under the symbol CNTX. Context Therapeutics filed confidentially on March 22, 2021. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
